Clinical-stage Australian Lifesciences company OncoSil Medical (ASX:OSL), has received an initial substantial holder notice from Regal Funds Management, with a 10.98% stake.
Regal now holds circa 45.5 million shares, purchased at $0.22.
The OncoSil treatment is an implantable nuclear medicine (radiotherapy) device that has been successfully piloted in pancreatic and liver cancer.
The device is inserted directly into the centre of the tumour using well established technology.
It has clinically demonstrated target tumour regression (tumour shrinkage) in both solid tumour indications of pancreatic and liver cancer.
Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.